Orum Therapeutics Inc is a Korea-based company principally engaged in the research and development of biopharmaceuticals. The Company is principally engaged in the research and development of new biopharmaceuticals for cancer and immune diseases based on its platforms.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
01/09/26	KRW 59,200.00	-8.92%	151,982
31/08/26	KRW 65,000.00	-1.52%	136,530
28/08/26	KRW 66,000.00	-1.20%	60,446
27/08/26	KRW 66,800.00	-2.05%	74,330
26/08/26	KRW 68,200.00	-3.54%	82,186

End-of-day quote Korea S.E.

More quotes

End-of-day quote Korea S.E. 01/09/2026			5-day change	1st Jan Change
59,200.00 ^KRW	-8.92%		-18.34%	-50.67%

23/08	Orum Therapeutics Receives FDA Clearance Of IND Application For ORM-1153, A Novel CD123-GSPT1 Degrader-Antibody Conjugate	CI
16/07	Alert wrongly tagged to Orum Therapeutics withdrawn	RE

Market Cap	1,286B 937M 808M 761M 693M 1.3B 88.95B 1.31B 8.99B 3.5B 45.25B 3.52B 3.44B 150B	P/E 2024 *	-	P/E 2025	-59.5x
Enterprise Value	1,179B 859M 741M 697M 635M 1.19B 81.54B 1.2B 8.24B 3.21B 41.48B 3.23B 3.16B 138B	EV / Sales 2024 *	-	EV / Sales 2025	103,580x
Free-Float	84.16%	Yield 2024 *	-	Yield 2025	-

23/08	Orum Therapeutics Receives FDA Clearance Of IND Application For ORM-1153, A Novel CD123-GSPT1 Degrader-Antibody Conjugate	CI
16/07	Alert wrongly tagged to Orum Therapeutics withdrawn	RE
18/04	Orum Therapeutics Presents New Preclinical Data on ORM-1153, A CD123-Targeting Degrader-Antibody Conjugate	CI
13/04	Orum Therapeutics, Inc. Appoints Maria Koehler and Geoff Meyerson to Board of Directors	CI
16/01	Orum Therapeutics, Inc. announced that it has received KRW 24.999873175 billion in funding from a group of investors	CI
05/01	Orum Therapeutics Appoints Chad May as Chief Scientific Officer	CI
18/12	Orum Therapeutics, Inc. announced that it expects to receive KRW 24.999873175 billion in funding from a group of investors	CI
04/11	Orum Therapeutics Announces Presentation of Preclinical Data for Orm-1153 At the 2025 American Society of Hematology Annual Meeting	CI
15/10/25	Orum Therapeutics Appoints Dorin Toader as Head of Platform Technology	CI
23/06/25	Orum Therapeutics, Inc.(KOSDAQ:A475830) added to S&P Global BMI Index	CI
07/02/25	Orum Therapeutics, Inc. has completed an IPO in the amount of KRW 50 billion.	CI
16/07/24	Orum Therapeutics Announces a Global, Multi-Target License and Option Agreement with Vertex Pharmaceuticals for the Use of Orum's TPD2 Technology to Develop Novel Degrader-Antibody Conjugates	CI

23/08	Orum Therapeutics Announces U.S. FDA Clearance of an IND Application for ORM-1153, a Novel CD123-GSPT1 Degrader-Antibody Conjugate	AQ
20/12	Orum Therapeutics Secures Approximately US$100 Million to Accelerate Development of Leading Degrader Antibody Conjugate Programs to Treat Serious Diseases	AQ
16/10/25	Orum Therapeutics Appoints Dr. Dorin Toader as Head of Platform Technology to Advance Orums Degrader-Antibody Conjugate Payload Platforms and Expand TPD Therapeutic Applications	AQ

Orum Therapeutics, Inc. Stock

Stocks

A475830

KR7475830006

Biotechnology & Medical Research

Valuation : Orum Therapeutics, Inc.

Chart: Orum Therapeutics, Inc.

Latest news : Orum Therapeutics, Inc.

Press Releases : Orum Therapeutics, Inc.

Quotes and Performance

Price Extremes

Managers and Directors : Orum Therapeutics, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

1 day	-8.92%
1 week	-18.34%
Current month	-8.92%
1 month	+32.74%
3 months	-12.68%
6 months	-54.57%
Current year	-50.67%

1 week	58,500	72,800
1 month	42,400	75,700
Current year	36,100	146,600
1 year	25,750	146,600
3 years	15,950	146,600
5 years	15,950	146,600
10 years	15,950	146,600

Manager	Title	Age	Since
Seung-Ju Lee CEO	Chief Executive Officer	52	17/08/2016
In-Tae Jeong DFI	Director of Finance/CFO	44	23/10/2023
Chad May CTO	Chief Tech/Sci/R&D Officer	-	05/01/2026

Director	Title	Age	Since
Seung-Ju Lee BRD	Director/Board Member	52	17/08/2016
In-Tae Jeong BRD	Director/Board Member	44	23/10/2023
Un-Nam Park BRD	Director/Board Member	55	01/04/2019

Date	Insider	Type	Main position	Quantity	% Market Cap.
21/2/25	Seung-Ju Lee	Free	Founder	3,388,000	-
21/2/25	In-Tae Jeong	Free	Chief Financial Officer	10,000	-
21/2/25	Un-Nam Park	Free	Director	60,000	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ORUM THERAPEUTICS, INC.	-8.92%	-18.34%	+130.35%	-	1.03B
WUXI APPTEC CO., LTD.	-0.25%	-0.92%	+49.47%	+89.45%	68.13B
ARGENX SE	+1.21%	+0.80%	+46.29%	+85.32%	63.6B
WUXI BIOLOGICS (CAYMAN) INC.	+1.31%	-5.21%	+37.52%	+12.07%	25.57B
INSMED INCORPORATED	-0.25%	-1.92%	-10.72%	+436.70%	26.6B
BIONTECH SE	+0.33%	-10.61%	+1.95%	-16.27%	25.52B
PHARMAESSENTIA CORPORATION	-6.09%	-12.08%	+226.11%	+375.00%	18.23B
GENMAB A/S	+1.18%	-2.23%	+30.87%	-19.04%	19.69B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-1.49%	-6.44%	+0.78%	+540.26%	15.16B
EXELIXIS, INC.	+4.12%	+0.30%	+52.03%	+150.18%	13.54B
Average	-0.89%	-4.78%	+56.46%	+183.74%	27.71B
Weighted average by Cap.	+0.11%	-2.90%	+45.54%	+143.88%

	2024	2025
Net sales	20.91B 15.24M 13.15M 12.37M 11.26M 21.18M 1.45B 21.3M 146M 56.9M 736M 57.22M 55.97M 2.44B	23.56M 17.18K 14.82K 13.94K 12.7K 23.88K 1.63M 24.01K 165K 64.13K 829K 64.49K 63.09K 2.75M
Net income	-5.74B -4.18M -3.61M -3.4M -3.09M -5.82M -397M -5.85M -40.14M -15.62M -202M -15.71M -15.37M -670M	-41.97B -30.59M -26.39M -24.82M -22.61M -42.53M -2.9B -42.76M -293M -114M -1.48B -115M -112M -4.9B
Net Debt	-90.47B -65.95M -56.89M -53.51M -48.75M -91.67M -6.26B -92.17M -633M -246M -3.18B -248M -242M -10.56B	-107B -78.07M -67.35M -63.35M -57.71M -109M -7.41B -109M -749M -291M -3.77B -293M -287M -12.5B